Private Market View

Hejia Pharmatech

Shijiazhuang, China · Founded 1999 · Privately Held (backing)

Last price · $/share
Implied valuation
Total raised
Last round

Key facts

  • Notable investors include Lin Nan Capital, Xin Ding Capital.
  • Status: Privately Held (backing).
Free account
See the evidence behind this price
  • ·The complete investor list — 2 names
  • ·Watchlist + deal alerts for Hejia Pharmatech
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Hejia Pharmatech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Hejia Pharmatech

Manufacturer of chemical compounds intended for pharmaceutical, industrial, and specialty applications. The company offers pharmaceutical intermediates such as active esters and acids for cephalosporin synthesis, raw materials like sodium salts of antibiotics, and fine chemicals including surfactants, polyols, and catalysts, enabling pharmaceutical and industrial markets to access a broad portfolio of synthesis-ready inputs, formulation components, and process enhancers for scalable production and specialized use cases.

Sector
Materials and Resources
HQ
Shijiazhuang, China
Founded
1999
Employees
547
Ownership
Privately Held (backing)
PA Mark — not yet priced

Hejia Pharmatech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Hejia Pharmatech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Hejia Pharmatech in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.